The effects of polymicrobial sepsis with diabetes mellitus on kidney tissues in ovariectomized rats

Abstract

Objectives: Sepsis model was used to understand the role of sustained hyperglycemia and ovariectomy, either separately or concomitantly, on the response of the activity of the nuclear factor kappa B (NF-κB) and the oxidative response in kidney. Subjects: Polymicrobial sepsis was induced by cecal ligation and puncture (CLP). Diabetes was induced in female rats using administration of alloxan. The rats were divided into five groups: sham control (group 1), ovariectomy (group 2), ovariectomy + sepsis (group 3), ovariectomy + diabetes (group 4), and ovariectomy + diabetic + sepsis (group 5). Results: In kidney tissues, the levels of lipid peroxidation (LPO) and glutathione (GSH) and the activity of catalase (CAT) were higher for groups 3, 4, 5 than the control groups. Superoxide dismutase (SOD) activity was lower for groups 3, 4, 5 than the control groups. We determined that CLP produced injury evident in the kidneys of rats when compared to the control group, whereas the severity of the injury was higher in the diabetes + ovariectomy + CLP group when compared to the CLP group. In immunohistochemical staining, we determined that CLP operation increased NF-κB activation. In the ovariectomized, septic, and diabetic group, NF-κB activation was significantly higher than other groups. Conclusions: Hyperglycemia and ovariectomy severely increased NF-κB activation and oxidant levels with the stages of our sepsis model. Ovariectomy resulted in general changes in metabolism, which are seen in the kidney with diabetes under sepsis conditions.

Keywords:

• kidney
• sepsis
• diabetes
• ovariectomy
• NF-κB
• rat
• oxidant

Acknowledgments

This research was conducted in the Laboratory of Pharmacology at Ataturk University, School of Medicine, Erzurum, Turkey, and the Laboratory of Histology and Embryology, School of Medicine at Ataturk University, Erzurum, Turkey. None of the authors has a commercial interest, financial interest, and/or other relationship with manufacturers of pharmaceuticals, laboratory supplies, and/or medical devices or with Commercial providers of medically related services.